BOWMAN, Edward Paul,CUA, Daniel J.,KASTELEIN, Robert A.,MILLER, Kathy Lynn,KLEINSCHEK, Melanie A.,BAK-JENSEN, Christian S.,BONIFACE, Katia,MCKENZIE, Brent,DE WAAL MALEFYT, Rene
申请号：
AU2014200946
公开号：
AU2014200946A1
申请日:
2014.02.24
申请国别(地区):
AU
年份:
2014
代理人:
摘要：
#$%^&*AU2014200946A120140313.pdf#####Abstract Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, 5 involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a proinflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute io phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative is disorders. 51397071 (GHMatters) P81806.AU.1 21102/14
